

Minimally invasive hepatectomy vs. thermoablation for single small (≤ 3 cm) hepatocellular carcinoma: A weighted real-life national comparison


Authors

Felice Giuliani, Simone Famularo, Sara Grasselli, ..., Davide Bernasconi, Francesco Ardito, Franco Trevisani

Correspondence

felice.giulianti@policlinicogemelli.it (F. Giuliani).

Graphical abstract



Highlights:

- Real-world data analysis based on two national registers.
- Laparoscopic liver resection ensured prolonged overall and recurrence-free survival compared with ablation.
- Laparoscopic liver resection significantly reduced the risk of early recurrence after treatment.
- These trends were confirmed even in subgroup analysis and after weighting all the possible differences among groups.

Impact and implications:

Percutaneous thermoablation is considered an appropriate alternative to liver resection for small (≤ 3 cm) single hepatocellular carcinoma because of not-inferior overall survival, although several authors reported increased recurrence risk. Whether videolaparoscopic liver resection could guarantee comparable survival but superior oncologic control of the disease is a matter of debate. This study comparing videolaparoscopy vs. thermoablation in a large national cohort of 1,465 patients observed that the former guaranteed significant prolonged OS (93 months [95% CI 75–110] vs. 60 months [95% CI 52–66] for the ablation group) and recurrence-free survival (26 months [95% CI 23–29] for ablation patients and 39 months [95% CI 30–55] for laparoscopic resection patients) even after weighting all the preoperative and oncologic differences among the groups. Our results clearly address the need to rethink the role of thermoablation for single small HCC as a second-line treatment when laparoscopic liver resection is not feasible.

Minimally invasive hepatectomy vs. thermoablation for single small (≤ 3 cm) hepatocellular carcinoma: A weighted real-life national comparison

Felice Giuliani^{1,*,†}, Simone Famularo^{1,2,†}, Sara Grasselli³, Angelo Sangiovanni⁴, Alessandro Vitale⁵, Giuseppe Cabibbo⁶, Andrea Lauterio⁷, Federica Cipriani⁸, Alice Saccomandi⁹, Marco Arru¹⁰, Elisa Pinto¹¹, Maurizia Rossana Brunetto¹², Maria Stella Franzè¹³, Camilla Graziosi¹⁴, Claudia Campani¹⁵, Fabio Marra¹⁵, Mariella Di Marco¹⁶, Mariarosaria Marseglia¹⁷, Valentina Santi¹⁸, Mario Capasso¹⁹, Alberto Masotto²⁰, Andrea Fontana²¹, Maurizio Iaria²², Alba Rocco²³, Matteo Serenari²⁴, Andrea Mega²⁵, Antonio Gasbarrini²⁶, Maria Corina Plaz Torres^{27,28}, Mattia Garancini²⁹, Simone Conci³⁰, Elton Dajti³¹, Pasquale Perri³², Rodolfo Sacco³³, Mariano Giglio³⁴, Cecilia Ferari³⁵, Michela De Angelis³⁶, Albert Troci³⁷, Donatella Magalotti³⁸, Daniele Nicolini³⁹, Giuseppe Zimmiti⁴⁰, Paola Germani⁴¹, Laura Schiada⁴², Maria Conticchio⁴³, Matteo Zanello⁴⁴, Maurizio Romano⁴⁵, Flavio Milana⁴⁶, Quirino Lai⁴⁷, Stefan Patauner⁴⁸, Antonio Frena⁴⁸, Massimo Rossi⁴⁷, Guido Torzilli⁴⁶, Giacomo Zanusi⁴⁵, Elio Jovine²⁴, Riccardo Memeo⁴³, Gianluca Svegliati-Baroni⁴², Paola Tarchi⁴¹, Moh'd Abu Hilal⁴⁰, Marco Vivarelli³⁹, Michele Crespi³⁷, Luigi Boccia³⁶, Guido Griseri³⁵, Roberto Ivan Troisi³⁴, Gian Luca Grazi⁴⁹, Francesco Azzaroli³¹, Andrea Ruzzenente³⁰, Fabrizio Romano²⁹, Edoardo G. Giannini^{27,28}, Matteo Cescon²⁴, Gerardo Nardone²³, Raffaele Dalla Valle²², Alessandro Ferrero²¹, Filomena Morisco¹⁹, Fabio Piscaglia¹⁷, Giorgia Ghittoni¹⁴, Carlo Saitta¹³, Filippo Pelizzaro¹¹, Gianpaolo Vidili¹⁰, Francesco Giuseppe Foschi⁹, Luca Aldrighetti⁸, Luciano De Carli⁷, Umberto Cillo⁵, Elisabetta Biasini³, Davide Bernasconi⁵⁰, Francesco Ardito^{1,‡}, Franco Trevisani^{18,‡}, for the HE.RC.O.LE.S. and the ITA.LI.CA. groups[§]

JHEP Reports 2025. vol. 7 | 1–12



Background & Aims: For patients with single small (≤ 3 cm) hepatocellular carcinoma ablation is the first-line treatment, although a high rate of recurrence has been reported. The aim was to compare videolaparoscopic liver resection (laparoscopic resection group) vs. percutaneous thermoablation (ablation group) in terms of overall survival, recurrence-free survival and early recurrence in a real-life national scenario.

Methods: The study is a retrospective collection with subsequent survival analysis. Data were collected from two Italian HCC registries, ITA.LI.CA and HE.RC.O.LE.S. An inverse probability of treatment weighting analysis was performed to balance baseline differences between groups. The Kaplan–Meier method and double-robust Cox multivariable regression were run to estimate the survival and the risk of mortality and recurrence.

Results: Between 2008 and 2022, 1,465 patients were enrolled. The laparoscopic resection group and ablation group consisted of 496 and 969 patients, respectively. At baseline, the ablation group had more advanced liver disease, with higher rates of cirrhosis (90.7% vs. 77.3%, $p < 0.001$) and Child-Pugh B status (18.4% vs. 8.8%, $p < 0.001$). After a median follow-up of 59 months and after weighting median overall survival was 60 months (95% CI 52–66) for the ablation group and 93 months (95% CI 75–110) for the laparoscopic resection group (hazard ratio [HR] 0.607, 95% CI 0.533–0.691, $p < 0.001$). Median recurrence-free survival was 26 months (95% CI 23–29) for the ablation group and 39 months (95% CI 30–55) for the laparoscopic resection group (HR 0.736, 95% CI 0.659–0.822, $p = 0.0013$). Laparoscopy was associated with a reduced risk of early recurrence (HR 0.747, 95% CI 0.655–0.853, $p = 0.011$).

Conclusions: This study provides real-world evidence that for patients with single ≤ 3 cm HCC, videolaparoscopic liver resection offers superior long-term oncological outcomes compared with thermoablation. These findings support the preference for surgical treatment in this patient population.

© 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and represents the fifth leading cause of cancer-

related deaths worldwide.¹ Despite advancements in viral hepatitis prevention and antiviral therapies, its incidence is projected to rise, particularly in Western countries, as a result of

* Corresponding author. Address: Hepatobiliary and General Surgery Unit, Foundation University Hospital “A. Gemelli” IRCCS, Sacred Heart Catholic University, Viale Agostino Gemelli 8, 00136 Rome, Italy.

E-mail address: felice.giuliano@policlinicogemelli.it (F. Giuliani).

† These authors share co-first authorship.

‡ These authors share co-last authorship.

§ For the list of HE.RC.O.LE.S and ITA.LI.CA contributors please see [Appendix 1](#).

<https://doi.org/10.1016/j.jhepr.2025.101420>



the increasing prevalence of metabolic-associated liver disease.² Currently, liver transplantation is considered the gold standard treatment, especially for HCC arising in the context of chronic liver disease.³ However, because of organ shortages, thermoablation and liver resection remain viable curative-intent options, particularly for patients with preserved liver function.⁴

In cases of early-detected small single HCCs, numerous observational studies and randomized clinical trials (RCTs) have sought to compare the outcomes of surgery and ablation to determine the most effective personalized management for these patients.⁵ Although some studies reported comparable outcomes in terms of survival and recurrence rates, others yielded conflicting results favoring one technique over the other.^{6–10} Nonetheless, these studies varied significantly in their definitions of ‘small HCC’ and, in some cases, did not specifically focus on this subset of patients. Consequently, meta-analyses based on these studies have produced controversial conclusions.^{11–13}

In response, clinical practice guidelines from both Western and Eastern societies recommend either surgical resection or ablation for HCC presenting as a single nodule <3 cm, with ablation being the preferred approach for nodules ≤2 cm in size or those located in deep areas.^{14–16}

One of the primary advantages of ablation over surgery is its minimally invasive nature, alongside superior cost-effectiveness and suitability for treating frail patients who are otherwise ineligible for surgery.^{17,18} However, the adoption of minimally invasive surgical techniques and advancements in perioperative management^{19,20} have significantly narrowed the gap between surgery and percutaneous ablative procedures in terms of invasiveness and postoperative care. As a result, comparing the medium-to long-term outcomes of these two treatments has become increasingly critical to guide therapeutic decision-making.

To provide additional insights into this highly nuanced context, the present study compared the outcomes of minimally invasive surgery and percutaneous thermoablation in a real-life national setting for patients with single small (≤3 cm) HCC.

Patients and methods

Registers information

This retrospective study evaluated data prospectively collected by two Italian databases on HCC, the ITA.LI.CA (Italian Liver Cancer) and the HE.RC.O.LE.S. (Hepatocarcinoma Recurrence on the Liver Study). The ITA.LI.CA patients were enrolled between 1996 and 2022 by 24 different centers, whereas the HE.RC.O.LE.S. cases were enrolled between 2008 and 2022 by 30 centers.²¹ More details are available in [Supplementary methods 1](#).

Study overview, patient selection, and study design

All consecutive adult (age ≥18 years) patients with a radiological and/or histological proven HCC who underwent minimally invasive (videolaparoscopic) liver resection or percutaneous thermoablation from January 2008 to December 2022 were considered for this study. Results are reported according to principles of Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).²² A check-

list is available within the supplementary materials. The laparoscopic resection group cohort was extracted by the HE.RC.O.LE.S. database, and the patients who underwent ablation were selected from the ITA.LI.CA database. The first register is a national database where patients treated by liver resection only (open or minimally invasive) are included. The latter is a hepatologic register where all the other treatments are collected but not liver resection.

Inclusion criteria were: (1) patients assigned to video-laparoscopic liver resection or percutaneous thermoablation as first HCC treatment without previous therapies; (2) evidence of single intrahepatic nodule with major diameter ≤3 cm. Exclusion criteria were: (1) extrahepatic tumor spread; (2) presence of macrovascular invasion; (3) missing data on the follow-up.

Selected patients were then divided into those who were treated by videolaparoscopic surgery (laparoscopic resection group) and those who underwent thermoablation (ablation group).

Causal question

What is the effect of laparoscopic surgery compared with percutaneous thermal ablation on overall survival in patients with a single HCC measuring ≤3 cm?

Study endpoints and follow-up

The primary endpoint was the overall survival (OS) across the two groups, measured as the difference in months between the date of treatment and that of death or the last follow-up available. The secondary endpoint was the recurrence-free survival (RFS), measured as the difference in months between the date of treatment and the date of the disease recurrence. In case of no recurrence, progression, or death, data were censored at the date of the last available follow-up visit. A recurrence before 24 months from the treatment was defined as ‘early recurrence’, and considered a surrogate of treatment strategy failure.

All patients were followed up using local protocols, which included measurement of serum alpha-fetoprotein (AFP), abdominal ultrasound, computed tomography (CT) scan or magnetic resonance imaging (MRI), and outpatient visits. Patient surveillance was closed at the end of December 2023.

Treatments

The indication for liver resection or thermoablation was provided by the multi-disciplinary board of each center including surgeons, hepatologists, oncologists, radiologists, interventional radiologists, and pathologists. The board decision was based on several factors, such as liver function, tumor burden (size and number of lesions, uni/bilobar disease, residual liver volume after resection, localization of the nodule), comorbidities, previous surgical history, patient’s opinion, and level of available scientific evidence to provide a patient-tailored treatment in line with the precision medicine approach and according to a personalized management of HCC patients. The laparoscopic technique was decided by the surgical team, according to their expertise and general behavior. The ablation group included both patients undergoing percutaneous radio-frequency ablation (RFA) or microwave ablation (MWA). Compared with RFA, the larger volume of active heating of

MWA offers the possibility to treat a larger area, at higher temperature with a less susceptibility to the heat-sink effect of blood flowing. The choice of one or another technique was made according to clinical scenario and local expertise.

Definitions

Comorbidities were summarized by the Charlson Comorbidity Index (CCI).²³ Eastern Cooperative Oncology Group - Performance Status (ECOG-PS) was measured at the first outpatient visit.^{24,25} The presence of cirrhosis was established before the treatment choice according to clinical, biochemical, endoscopic, and, if available, pathological information. The presence of esophagogastric varices was assessed endoscopically. Liver function was estimated using both the model for end-stage liver disease (MELD) score²⁶ and the Child-Pugh-Turcotte (CPT) class.²⁷ Biochemical variables were obtained within 2 weeks from the assigned treatment. The number and size of nodules and presence of vascular invasion were assessed by CT scan or MRI, and each center declared that images were scrutinized by expert and dedicated radiologists. The extension of liver resection was defined as minor or major, based on the Brisbane nomenclature.²⁸

Statistical analysis

The sample description was done using median and IQR for numeric variables and number and proportion for categorical variables. Mann-Whitney and Fisher tests were used to compare baseline patient characteristics between the two treatment groups. The issue of unmeasured values in some covariates (caused by a 'missing at random' [MAR] mechanism²⁹) was handled by using the multiple imputation method, and final estimates of the coefficients and standard errors were obtained by pooling model results on 10 imputed datasets.³⁰ After the univariate comparison of baseline characteristics between treatment groups, all variables showing a p value <0.05 and with a known prognostic role were considered as confounders and included in a multiple logistic regression model. The model was fitted to each of the 10 datasets to estimate the propensity score (PS) (in our model: sex, ECOG-PS, alcohol consumption, cirrhosis, CPT class, presence of varices, BMI, CCI, platelet count, and AFP). For each patient, the estimated PS was used to run an inverse probability of treatment weighting (IPTW) analysis^{31,32} (target estimand: average treatment effect). For continuous variables, splines with a $df = 5$ were applied. The generated weights over the 99th percentile were trimmed to stabilize the effect. After weighting each patient, two pseudo-populations of size different from the original ones but with comparable baseline characteristics were obtained. Standardized mean differences of confounders were calculated in both the original and weighted populations to check the balance between treatment groups, and a 'Love' plot (that graphically displays the pre and post effects of propensity scores) was generated. Survival was estimated by the Kaplan-Meier method, and comparisons were performed by the log-rank test before the IPTW and with a robust test after IPTW. A univariate Cox regression analysis was used to evaluate the prognostic role of baseline variables. Variables that were associated with OS by a p value <0.05 were included in the multivariable model, together with other well-known factors related to mortality. These data were reported as hazard ratio

(HR) and 95% CI. The same analysis was performed for RFS. As a sensitivity analysis, a 1:1 nearest neighbor propensity score matching (target estimand: average treatment effect in the treated group) was run with a caliper of 0.1 with the same variables used for the IPTW.

The risk analysis for mortality and recurrence according to the treatment received was done also in different subgroups, after re-estimating the PS and the weights. The superiority of the laparoscopic resection over ablation was assessed in case a 5% significance level was achieved. Non-inferiority of laparoscopic resection over ablation was assessed by establishing the upper bound of the confidence interval for the difference in treatment effects (hazard ratio) that falls below a predefined margin (1.2). This value was chosen by clinical relevance according to the authors' opinion. Because of the retrospective nature of the study, this last measurement should be considered an exploratory analysis, and for that the hypothesis test and the consequent p value was not reported to avoid any unpowered analysis.

All the analyses were computed by using the open-source R software (v. 4.2.2, specific packages used: MICE, WeightThem, Cobalt, Survival, Survminer).

Results

Between 2008 and 2022, 13,608 patients (8,166 in the ITA.L-I.CA. register and 5,442 in the HE.RC.O.LE.S. register) were enrolled. Of these, 1,465 were included according to the inclusion and exclusion criteria: 496 were treated by laparoscopic hepatic resection (laparoscopic resection group) and 969 by percutaneous thermoablation (ablation group). A flow chart is available in Fig. S1.

At the baseline, 304 (31.4%) patients in the ablation group and 124 (25.0%) in the laparoscopic resection group were female ($p = 0.013$). Median age was 70 (IQR 62–76) years and 69 (IQR 61–75) years for the ablation and laparoscopic resection groups, respectively ($p = 0.138$). Median CCI score was 7 (IQR 6–9) and 6 (IQR 4–7), respectively ($p <0.001$). Alcohol consumption was the etiology of the underlying liver disease in 290 (31.9%) patients and 107 (21.9%) in the ablation and laparoscopic resection group, respectively ($p <0.001$). Cirrhosis was detected among 863 (90.7%) patients in the ablation group and 382 (77.3%) in the laparoscopic resection group (<0.001), and 162 (18.4%) patients and 36 (8.8%) patients were CPT grade B respectively ($p <0.001$). Esophagogastric varices were present in 433 (50.1%) and 139 (31.2%) patients in the ablation and laparoscopic resection groups ($p <0.001$). Regarding the tumor burden, median size was 2.00 cm (IQR 1.50–2.50) for ablation and 2.00 cm (IQR 1.50–2.40) for laparoscopic resection groups ($p = 0.965$); median AFP was 7.00 ng/dl (IQR 3.60–21.00) and 8.00 ng/dl (IQR 3.80–43.00) for ablation and laparoscopic resection groups, respectively ($p = 0.042$). These and other baseline characteristics are reported in Table 1. The rate of missing data in the whole dataset is reported in Table S1. Among the laparoscopic resection cohort, 334 (67.3%) patients underwent non-anatomic resection, and 162 (32.7%) underwent anatomic resection.

Over a median follow-up of 59 months (IQR 30–93), 637 (43.5%) patients died, and 792 (54.1%) had a recurrence. Median OS was 61 months (95% CI 56–66) for patients who underwent ablation and 90 months (95% CI 75–107) for those

Table 1. Baseline characteristics of the observed cohort.

	Ablation	Laparoscopic resection	p value
n	969	496	
Age (median [IQR])	70.00 [62.00–76.00]	69.00 [61.00–75.00]	0.138
Females (%)	304 (31.4)	124 (25.0)	0.016
Charlson Comorbidity Index (median [IQR])	7.00 [6.00–9.00]	6.00 [4.00–7.00]	<0.001
ECOG PS (%)			0.001
0	850 (87.7)	421 (84.8)	
1	97 (10.0)	65 (13.2)	
2	22 (2.3)	10 (2.0)	
Alcohol consumption (%)	290 (31.9)	107 (21.9)	<0.001
HBV+ (%)	93 (11.1)	87 (17.9)	0.001
HCV+ (%)	568 (63.5)	295 (59.8)	0.193
Cirrhosis (%)	863 (90.7)	382 (77.3)	<0.001
Child–Pugh grade (%)			<0.001
A	714 (81.1)	374 (91.2)	
B	162 (18.4)	36 (8.8)	
C	4 (0.5)	0 (0.0)	
Varices (%)	433 (50.1)	139 (31.2)	<0.001
MELD score (median [IQR])	8.03 [7.00–10.00]	8.00 [7.00–10.00]	0.358
Size, cm (median [IQR])	2.00 [1.50–2.50]	2.00 [1.50–2.40]	0.965
AFP, mg/dl (median [IQR])	7.00 [3.60–21.00]	8.00 [3.80–43.00]	0.042
Albumin, g/dl (median [IQR])	3.80 [3.50–4.10]	3.90 [3.50–4.30]	0.065
INR (median [IQR])	1.12 [1.04–1.20]	1.10 [1.04–1.22]	0.706
Platelet count $\times 10^9/L$ (median [IQR])	122.00 [84.00–165.00]	142.00 [92.00–187.00]	<0.001
MVI+ (%)	–	136 (27.4)	–
Satellitosis (%)	–	44 (8.8)	–
Anatomic resection (%)	–	179 (36.1)	–

Continuous variables were compared using the Mann–Whitney test and categorical variables were compared with the Fisher test. AFP, alpha-fetoprotein; ECOG PS Eastern Cooperative Oncologic Group – Performance Status; MELD, model for end-stage liver disease; MVI, microvascular invasion at the histologic specimen; VLS, videolaparoscopy.

who underwent laparoscopic resection ($p < 0.001$). Median RFS was 25 months (95% CI 23–29) for the ablation group and 38 months (95% CI 30–55) for the laparoscopic resection group ($p < 0.001$). The survival curves are depicted in Fig. 1A and B.

Survival analysis after IPTW

The IPTW model adopted to balance the baseline differences between groups included: sex, ECOG-PS, alcohol consumption, cirrhosis, CPT class, presence of varices, BMI, CCI, platelet count, and AFP. The effect of the IPTW is depicted in Fig. 2, and the standard mean differences before and after the weighting are reported in Table S2. The weights distribution by treatment arm is depicted in Fig. S2: the overlapping of the weights' range allowed confirmation of the positivity assumption. After the weighting, two generated pseudo-populations consisted of 1,290.176 pseudo-patients in the ablation group and 1,088.217 pseudo-patients in the laparoscopic resection group.

In the weighted cohort, median OS was 60 months (95% CI 52–66) for the ablation group and 93 months (95% CI 75–110) for the laparoscopic resection group (HR 0.607, 95% CI 0.533–0.691, $p < 0.001$) (Fig. 1C). At the multivariable double robust Cox regression, being treated by laparoscopic resection (HR 0.714, 95% CI 0.57–0.89, $p = 0.003$), ECOG-PS 2 (HR 2.108, 95% CI 1.30–3.40, $p = 0.002$), being Child–Pugh B (HR 1.729, 95% CI 1.28–2.33, $p < 0.001$), age (HR 1.012, 95% CI 1.00–1.02, $p = 0.017$) and an early recurrence after treatment (HR 1.781, 95% CI 1.46–2.16, $p < 0.001$) were independently associated with the OS (Table 2). The effect of the treatment was tested also in different subgroups (exploratory analysis), and the results were depicted in Fig. 3A. Briefly, in case of tumors ≤ 2 cm, laparoscopic resection (HR 0.656, 95% CI 0.48–0.89) was associated with OS.

Median RFS was 26 months (95% CI 23–29) for ablation patients and 39 months (95% CI 30–55) for laparoscopic resection patients (HR 0.736, 95% CI 0.659–0.822, $p = 0.0013$) (Fig. 1D). At the multivariable analysis, being treated by laparoscopic resection (HR 0.757, 95% CI 0.62–0.91, $p = 0.004$) and presence of cirrhosis (HR 1.387, 95% CI 1.05–1.81, $p = 0.017$) were independently associated with the risk of recurrence (Table 3). The effect of the treatments was tested also in different subgroups (exploratory analysis), and the results are depicted in Fig. 3B. Briefly, laparoscopic resection was not inferior (HR 0.757, 95% CI 0.56–1.02) to ablation in determining the risk of recurrence for tumors ≤ 2 cm.

A sensitivity analysis was done by repeating the survival estimation after propensity score matching to confirm the stability of the IPTW results: with the same variables considered for the IPTW, 323 patients were correctly matched per each group. The effect of the matching has been depicted in Fig. S3. Median OS was 56 months (95% CI 50–66) for ablation and 87 months (95% CI 74–107) for laparoscopic resection. Median RFS were 24 months (95% CI 20–29) and 39 (95% CI 30–64) for ablation and laparoscopic resection groups, respectively. Survival curves were depicted in Fig. S4 (OS) and 5 (RFS).

Pattern of recurrence and following treatments

Considering the 'early' recurrence, after IPTW, patients who underwent ablation showed 6-, 12-, and 24-month early RFS of 84.7%, 72.8%, and 52.1% respectively, whereas for those who had a laparoscopic resection these figures increased to 87.9%, 77.2%, and 62.3%, respectively (HR 0.747, 95% CI 0.655–0.853, $p = 0.011$, Fig. 4).

An intrahepatic recurrence was observed in 485 (85.4%) and 178 (79.5%) patients in the ablation and laparoscopic resection




Fig. 1. Survival curves between patients treated by videolaparoscopic liver resection (laparoscopic resection group) or by thermoablation. Overall survival (A) before IPTW and (C) after IPTW. Recurrence-free survival (B) before IPTW and (D) after IPTW. Comparison among groups was made using the log-rank test before weighting and by double-robust univariate Cox regression after the weighting.

groups, respectively, and an extrahepatic spread was present in nine (1.6%) and 12 (5.4%) patients, respectively ($p = 0.010$). A bilobar intrahepatic recurrence was observed in 110 (19.4%) and 41 (18.3%) patients of the ablation and laparoscopic

resection groups, respectively ($p < 0.001$). The median number of recurrent nodules was 1 (IQR 1–2) in the ablation and 1 (IQR 1–3) in the laparoscopic resection groups ($p = 0.004$). The median size of the recurrent nodule was 2.0 cm (IQR 1.40–2.70)




Fig. 2. 'Love' plot depicting the effect of the treatment weighting (IPTW) in terms of mean difference. The continuous black line represents the best possible weighting among variables, and the area among the two dashed lines represent an optimal balance obtained after IPTW. The red dots are the mean differences between groups for that variable before the weighting, and the blue dots are the mean difference after the weighting. 'Ns' before a continuous variable means that splines were applied to model that variable, and the relative total number of degrees of freedom (df) was indicated, with the reported results of each one of them. ECOG-PS, Eastern Cooperative Oncology Group - Performance Status; IPTW, inverse probability of treatment weighting.

Table 2. Univariate and multivariate double robust Cox regression to predict the risk of overall mortality.

Variable	Univariable				Multivariable			
	HR	95% CI – low	95% CI – up	p value	HR	95% CI – low	95% CI – up	p value
Female (vs. male)	0.957	0.838	1.093	0.6844				
Laparoscopic resection (vs. ablation)	0.607	0.533	0.691	<0.001	0.714	0.571	0.893	0.0031
ECOG PS 1 (vs. 0)	1.127	0.921	1.380	0.4469	1.104	0.822	1.482	0.5121
ECOG PS 2 (vs. 0)	2.562	1.865	3.520	0.0003	2.108	1.306	3.403	0.0023
ECOG PS 3 (vs. 0)	4.947	1.853	13.208	0.0003	7.571	3.354	17.091	<0.001
Alcohol consumption (vs. not)	1.083	0.937	1.252	0.4775				
HBV+ (vs. neg)	1.037	0.866	1.243	0.7788				
HCV+ (vs. neg)	0.887	0.781	1.007	0.2249				
Cirrhosis (vs. not)	1.553	1.290	1.869	0.0057	1.275	0.911	1.784	0.1563
CPT class B (vs. A)	2.068	1.756	2.435	<0.001	1.729	1.280	2.334	0.0004
Varices (vs. not)	1.199	1.059	1.356	0.0674				
BMI	1.002	0.987	1.016	0.8884				
MELD (per unit)	1.019	1.000	1.038	0.1750				
N. nodules	0.844	0.615	1.158	0.4181				
Size (per cm)	1.075	0.981	1.178	0.3078				
Albumin (per unit)	0.757	0.680	0.843	0.0014	0.885	0.739	1.059	0.1816
INR (per unit)	1.000	0.996	1.004	<0.001	0.811	0.542	1.213	0.3083
AFP (per unit)	1.000	1.000	1.000	0.0118	1.000	1.000	1.000	0.7080
Age (per year)	1.009	1.003	1.015	0.0535	1.012	1.002	1.022	0.0172
Early recurrence (vs. not)	1.914	1.692	2.165	<0.001	1.781	1.465	2.165	<0.001
Charlson Comorbidity Index (per point)	1.071	1.049	1.094	0.0010	1.007	0.962	1.053	0.7718

Univariate and multivariate Cox regression was used to test the hypothesis. AFP alpha-fetoprotein; CPT, Child–Pugh–Turcotte score; ECOG PS Eastern Cooperative Oncologic Group - Performance Status; HR, hazard ratio; INR, International normalized ratio; low, 95% CI lower limit; MELD, model for end-stage liver disease; up, 95% CI upper limit; VLS, videolaparoscopy.




Fig. 3. Exploratory analysis: Forest plot reporting the effect of the treatment (after weighting) among different subgroups. The red dashed line represents the non-inferiority point adopted in this study. (A) The effect of the treatment on overall survival (OS). (B) The effect of the treatment on recurrence-free-survival. Comparison among groups was made by double-robust univariate Cox regression after the weighting.

Table 3. Univariate and multivariate double-robust Cox regression to estimate the risk of recurrence.

Variable	Univariable				Multivariable			
	HR	95% CI – low	95% CI – up	p value	HR	95% CI –low	95% CI – up	p value
Female (vs. male)	0.924	0.820	1.041	0.4183				
Laparoscopic resection (vs. ablation)	0.736	0.659	0.822	0.0013	0.757	0.624	0.919	0.0048
ECOG PS 1 (vs. 0)	0.947	0.792	1.132	0.7054				
ECOG PS 2 (vs. 0)	0.806	0.522	1.243	0.5705				
Alcohol consumption (vs. not)	1.214	1.073	1.373	0.0699				
HBV+ (vs. neg)	1.027	0.874	1.206	0.8443				
HCV+ (vs. neg)	1.053	0.939	1.179	0.5801				
Cirrhosis (vs. not)	1.475	1.261	1.725	0.0044	1.387	1.059	1.816	0.0176
CPT class B (vs. A)	1.124	0.941	1.343	0.4267				
Varices (vs. not)	1.233	1.105	1.376	0.0248	1.169	0.977	1.399	0.0885
BM	1.011	0.998	1.023	0.3040				
MELD (per unit)	0.985	0.969	1.001	0.2220				
N. nodules	0.792	0.585	1.071	0.1907				
Size (per cm)	1.119	1.029	1.216	0.0960				
Albumin (per unit)	0.949	0.884	1.018	0.2231				
INR (per unit)	1.000	1.000	1.000	0.4069				
AFP (per unit)	1.000	1.000	1.000	0.1614				
Age (per year)	0.994	0.989	0.999	0.1432				

Univariate and multivariate Cox regression was used to test the hypothesis. AFP, alpha-fetoprotein; CPT, Child–Pugh–Turcotte score; ECOG PS Eastern Cooperative Oncologic Group Performance Status; HR, hazard ratio; INR, International normalized ratio; low, 95% CI lower limit; MELD model for end stage liver disease; up, 95% CI upper limit; VLS, videolaparoscopy.




Fig. 4. Survival curve reporting the early-recurrence free survival between the two treatment groups. Comparison among groups was made using univariate double-robust Cox regression.

and 2.0 cm (1.35–2.85) in the ablation and laparoscopic resection groups, respectively ($p = 0.932$).

Five hundred and sixty-eight (58.6%) patients treated by ablation and 224 (45.2%) treated by laparoscopic resection had a disease recurrence. This was treated by liver transplant in 22 (3.9%) and 14 (6.2%) cases of ablation and laparoscopic resection groups, respectively; by hepatectomy in 45 (7.9%) and 33 (14.7%), respectively; by thermoablation in 197 (34.7%) and 36 (16.1%), respectively; by transarterial chemo-embolization in 146 (25.7%) and 57 (25.4%), respectively; by systemic treatments in 24 (4.2%) and 25 (11.2%), respectively ($p < 0.001$). Overall, a curative strategy for the recurrence was adopted in 264 (46.5%) patients of the ablation and 83 (37.1%) patients of the laparoscopic resection groups.

Discussion

Several previous reports have analyzed the outcomes of surgical resection and ablation, even though differences in indications for these treatments are well-recognized.^{5,11} Typically, in the panorama of curative options, surgery is reserved for patients with larger tumors that are technically resectable, preserving enough liver remnant supporting hepatic functional reserve. Instead, patients with multiple comorbidities and/or a more deteriorated hepatic synthesis or particularly frail more often undergo ablation.^{14,15}

To define the indication for these two treatments better, numerous observational studies and RCTs have been conducted.^{6–10} However, the heterogeneity of the enrolled patients in terms of tumor burden, tumor location, or vascular contact, does not permit to achieve a solid evidence-based indication guiding the treatment decision in clinical practice. Among them, one RCT by Huang *et al.* [8] reported benefits in OS and RFS for surgery compared with ablation for HCC within Milan criteria. In

the SURF trial,¹⁰ surgery and ablation showed comparable oncologic results; however, patients with difficult tumor location were excluded, affecting a true comparison with surgery. Moreover, a recent meta-analysis suggests that RFA may offer better OS outcomes compared with minimally invasive surgery for single nodule presentations.³³

This ambiguous scenario prompted us to conduct a study including a higher number of patients than the meta-analysis itself, on a real-life basis, in which the comparison between techniques was made in a well-defined oncologic setting – single and small (≤ 3 cm) HCC – where the uncertainty is maximal. It revealed a statistically significant, and clinically relevant, improvement in both OS and RFS when the tumor was treated with laparoscopic resection compared with ablation. In fact, in surgical patients the mortality risk was decreased by nearly 29%, and the risk of recurrence by nearly 25%, as confirmed in the weighted population, where the baseline's confounders were balanced. In 2013, Pompili *et al.*³⁴ reported comparable OS among surgery and ablation in another Italian national cohort, with the latter showing a slightly longer 4-year OS (66%) when compared with our result (near 60%). Although few of the present authors participated in that study, the present study derived from two large national real-world registers, with a larger number of participating centers and patients included a longer median follow-up. The study of Pompili *et al.* included referral centers; however, this study is based on national data, without restriction regarding the case volume. Reference centers may introduce selection bias by case selection, which do not reflect the broader patient population. Conversely, including a diverse range of centers, from small community hospitals to large academic institutions, provides a more representative sample of real-world clinical practice. Moreover, our study included patients regardless of their underlying liver function, whereas the previous study selected only Child–Pugh A patients. Nevertheless, in 2013 the number of laparoscopic cases was very small, and the relative non-inferiority of ablation over resection could be explained by the negative impact of open surgery in those with liver cirrhosis. This constataion led to develop the present study, to verify if laparoscopy could change the scenario, as effectively our results seem to demonstrate.

The favorable effect on RFS is somehow already accepted in the literature, as several authors¹ have reported an increased risk of recurrence and, particularly, of local recurrence with ablation, because this therapy focuses on eliminating target lesions, whereas surgical resection also removes a certain portion of liver tissue surrounding the tumor, thereby reducing the risk of leaving residual tumor tissue and satellites. In addition, it has been recently reported that biologic factors could be implied in the mechanism of recurrence after ablation, like the induction of epithelial-mesenchymal transition, promotion of angiogenesis, activation of autophagy, non-coding RNA changing, and modifications of the tumor environment.³⁵

However, this drawback of ablation has been partially accepted because of the lower invasiveness and costs associated with an OS comparable with liver resection. The results of the present study disprove this position. In our cohort, patients submitted to ablation not only had a lower OS and an increased rate of overall recurrence, but also a higher risk of 'early' recurrence compared with surgical patients. Because early recurrence, particularly when it occurs near to the treated

lesion, can be considered a postoperative growth of unresected cancer tissue (failure of treatment), our results further support the reason previously discussed: an enucleo-ablation of the tumor is not enough to treat this disease radically.^{15,36}

To overcome this risk, anatomic or sub-anatomic resections have been adopted as the standard treatments in most resected patients. In fact, the presence of segmental microvascular invasion (MVI) or satellitosis is high also in the case of single small HCC (in our cohort MVI = 27.4% and satellitosis = 8.8%), and an effective local control is not achievable without a proper removal of that area.³⁷ The 'early' recurrence was an independent predictor of OS too, regardless of the treatment utilized. This means that a technique that leads to an increased rate of early recurrence should be carefully proposed, when minimally invasive resection could be offered to patients. Although ablation is considered to be repeatable in case of local failure until a definitive local control, in our real-life study this happened only up to 34.7% of patients who experienced a recurrence after ablation. Although the reason for not repeating the ablation cannot be reported according to the data collected in the registers, this is a real-life snapshot of what happens. Even if multiple repeated ablations could be efficient, actually this was not the first strategy adopted in most patients. Because of this, submitting those patients to ablation significantly increases the oncologic patients' risk, without a certainty of being able to repeat ablation in case of relapse. Similar observations, particularly in case of ablation for tumors between 2 and 3 cm, were recently reported.^{10,38}

The superiority of laparoscopic resection over ablation in terms of OS was confirmed also in subgroup analysis, particularly in the cohort of patients with a tumor size <2 cm, confirming the advantage of laparoscopic resection, when feasible, for any tumor characteristics. However, the exploratory nature of such analysis should be carefully evaluated in interpreting this result.

Our results came from a weighted analysis that took into account all the available confounders in determining the oncologic risk. The multivariable analysis indicates that the risk of recurrence, early recurrence, and OS was independently associated not only with the curative therapy used, but also with other well-known factors, such as age, presence of cirrhosis, its severity, and comorbidities. At baseline, patients undergoing ablation were more compromised, with significantly more deteriorated liver function, high rate of varices, and comorbidities. For frail patients, ablation should be theoretically preferred, because the perioperative risk of a liver resection could overcome the oncologic benefit. Nevertheless, *Giulianti et al.*³⁹ recently reported optimal short-term outcomes when a minimally invasive resection was adopted for small HCC, almost comparable to the ones obtained in the case of percutaneous ablation. However, other authors did not confirm this result,³³ and probably a randomized clinical trial could be the only way to clarify definitively if the laparoscopic approach is equivalent also in terms of perioperative risk. Our results

should be interpreted in light of a therapeutic hierarchy strategy,⁴⁰ which postulates that the choice between resection or ablation is not dependent on the morphologic presentation (number, size, etc.) of the tumor, but should be guided by the technical feasibility and the patient risk evaluated by a multidisciplinary tumor board considering many clinical factors and patient opinion. Given that, after transplantation, liver resection is the best option, it should be preferred and, if the patient's risk is deemed to be high, ablation becomes the best choice, being able to ensure an acceptable (although inferior to surgery) survival.

Limitations of our study. First, the retrospective nature of the analysis poses a challenge regarding the comparison between the two treatments, partially mitigated by the weighting technique. Secondly, the choice between videolaparoscopy and ablation was not driven by a pre-defined algorithm, and the number of patients excluded from surgery by clinical or technical reasons could not be assessed. This could have revealed more consistent conclusions. Because of the oncologic nature of the two databases that provided the cases for the analysis, no comparison was possible to define the best treatment in terms of perioperative outcomes, such as rate of complications or length of stay. Moreover, RFA and MWA were considered together in the ablation group because they were recorded together in the ITA.LI.CA. register. Although these techniques showed comparable long-term results (even with different technical applications), treating them as a unique group could have driven bias, particularly in terms of local recurrence. This last information was not reported in the ITA.LI.CA. dataset, leading to the impossibility to estimate properly the risk of local recurrence under ablation approaches. This has been partially mitigated by adopting the parameter of early recurrence, which could be considered a sort of surrogate. Nevertheless, it is important to acknowledge that early recurrence and local tumor progression are distinct oncologic events. Local tumor progression refers specifically to residual or regrowth of the tumor at the original ablation site, often as a result of incomplete ablation, whereas early recurrence encompasses both local and distant recurrences and may be influenced by biological tumor aggressiveness rather than solely reflecting the efficacy of local treatment. Although the diagnosis was histologically proven for the surgical patients, in the ablation group the diagnosis was confirmed by the radiologic interpretation of the preoperative imaging made by dedicated radiologists. However, the study did not provide imaging centralization for re-evaluation. Finally, the unretrievable data on tumor locations (superficial vs. deep located nodules, vascular contacts etc.) could introduce bias in the comparison among the two treatments, probably reducing the performance of the ablation group. To conclude, our findings strongly advocate for laparoscopic resection over ablation in patients with single HCC ≤3 cm in size, and support the importance of considering minimally invasive resection whenever clinically feasible, addressing most critical patients to referral centers.

Affiliations

¹Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Catholic University of the Sacred Heart, Rome, Italy; ²IRCAD, Research Institute Against Cancer of the Digestive System, Strasbourg, France; ³Department of Medicine and Surgery, Infectious Diseases and Hepatology Unit, University of Parma and Azienda Ospedaliero-Universitaria of Parma, Parma, Italy; ⁴Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and C.R.C. "A.M. & A. Migliavacca Center for Liver Disease", Milan, Italy; ⁵Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padova, Second General Surgical Unit, Padova Teaching Hospital, Padua, Italy; ⁶Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties (PROMISE), Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy; ⁷General

Surgery and Abdominal Organ Transplantation, ASST Grande Ospedale Metropolitano Milano Niguarda; School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; ⁸Hepatobiliary Surgery Division, "Vita e Salute" University, Ospedale San Raffaele IRCCS, Milan, Italy; ⁹Department of Internal Medicine, Ospedale per gli Infermi di Faenza, Faenza, Italy; ¹⁰Department of Medicine, Surgery and Pharmacy, Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy; ¹¹Department of Surgery, Oncology and Gastroenterology, Gastroenterology Unit, University of Padua, Padua, Italy; ¹²Department of Clinical and Experimental Medicine, Hepatology and Liver Physiopathology Laboratory, University Hospital of Pisa, Pisa, Italy; ¹³Department of Clinical and Experimental Medicine, Clinical and Molecular Hepatology Unit, University of Messina, Messina, Italy; ¹⁴Gastroenterology Unit, Belcolle Hospital, Viterbo, Italy; ¹⁵Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Florence, Florence, Italy; ¹⁶Medicine Unit, Bolognini Hospital, Seriate, Italy; ¹⁷Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ¹⁸Unit of Semeiotics, Liver and Alcohol Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ¹⁹Department of Clinical Medicine and Surgery, Diseases of the Liver and Biliary System Unit, University of Naples "Federico II", Naples, Italy; ²⁰Gastroenterology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negar, Italy; ²¹Department of General and Oncological Surgery, Maurizio Hospital "Umberto I", Turin, Italy; ²²Department of General and Specialized Surgery, Division of General Surgery, Parma University Hospital, Parma, Italy; ²³Department of Clinical Medicine and Surgery, Hepato-Gastroenterology Unit, University of Naples "Federico II", Naples, Italy; ²⁴Hepatobiliary Surgery and Transplant Unit, Policlinico Sant'Orsola IRCCS, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; ²⁵Gastroenterology Unit, Bolzano Regional Hospital, Bolzano, Italy; ²⁶Liver Unit, CEMAD – Centro Malattie Dell'Apparato Digerente, Medicina Interna e Gastroenterologia, Università Cattolica Del Sacro Cuore, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy; ²⁷Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy; ²⁸IRCCS Ospedale Policlinico San Martino, Genoa, Italy; ²⁹School of Medicine and Surgery, University of Milano-Bicocca; IRCCS San Gerardo Dei Tintori Hospital, Monza, Italy; ³⁰Division of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy; ³¹Division of Gastroenterology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ³²Division of Hepatobiliarypancreatic Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy; ³³Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, Foggia, Italy; ³⁴Division of Hepato-biliary-pancreatic, Minimally Invasive and Robotic Surgery, and Transplantation Service Federico II University Hospital, Naples, Italy; ³⁵HPB Surgical Unit, San Paolo Hospital, Savona, Italy; ³⁶Department of General Surgery, Ospedale Carlo Poma, Mantua, Italy; ³⁷Department of Surgery, L. Sacco Hospital, Milan, Italy; ³⁸Division of Internal Medicine, Neurovascular and Hepatometabolic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ³⁹HPB Surgery and Transplantation Unit, Department of Clinical and Experimental Medicine, Polytechnic University of Marche, Ancona, Italy; ⁴⁰Department of General Surgery, Poliambulanza Foundation Hospital, Brescia, Italy; ⁴¹Division of General Surgery, Department of Medical and Surgical Sciences, ASUGI, Trieste, Italy; ⁴²Liver Injury and Transplant Unit, Polytechnic University of Marche, Ancona, Italy; ⁴³Department of Hepato-Pancreatic-Biliary Surgery, "F. Miulli" General Regional Hospital, Acquaviva Delle Fonti, Bari, Italy; ⁴⁴Department of Medicine and Surgery, LUM University, Casamassima, Bari, Italy; ⁴⁵Alma Mater Studiorum, University of Bologna, AOU Sant'Orsola Malpighi, IRCCS at Maggiore Hospital, Bologna, Italy; ⁴⁶Department of Surgical, Oncological and Gastroenterological Science (DISCOG), University of Padua, Hepatobiliary and Pancreatic Surgery Unit - Treviso Hospital, Italy; ⁴⁷Department of Hepatobiliary and General Surgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; ⁴⁸General Surgery and Organ Transplantation Unit, Sapienza University of Rome, Umberto I Polyclinic of Rome, Rome, Italy; ⁴⁹Department of General and Pediatric Surgery, Bolzano Central Hospital, Bolzano, Italy; ⁵⁰HepatoBiliaryPancreatic Unit - AOU Careggi - University of Florence, Florence, Italy; ⁵¹Center of Biostatistics for Clinical Epidemiology, School of Medicine and Surgery, University of Milan - Bicocca, Monza, Italy

Abbreviations

AFP, alpha-fetoprotein; ATE, average treatment effect; CCI, Charlson Comorbidity Index; CPT, Child–Pugh–Turcotte; CT, computed tomography; ECOG-PS, Eastern Cooperative Oncology Group - Performance Status; HCC, Hepatocellular carcinoma; HR, hazard ratio; INR, International normalized ratio; IPTW, inverse probability of treatment weighting; LTP, local tumor progression; MAR, missing at random; MELD, model for end-stage liver disease; MRI, magnetic resonance imaging; MVI, microvascular invasion; MWA, microwave ablation; OS, overall survival; PS, propensity score; RCT, randomized clinical trial; RFA, radiofrequency ablation; RFS, recurrence-free survival; VLS, videolaparoscopy.

Financial support

No funds were obtained for the present study.

Conflict of interest

The authors of this study declare that they do not have any conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

Conceptualization: FG. Methodology: SF, FTrevisani. Formal analysis: SF, DPB. Investigation: FRazionale, GM, AO, GA, PR, CCammà, CCelsa, PG, CMG, GR, MVG, RC, AG, MSalvato, RDC, FRatti, LN, AB, FC, LI, MF, NR, FF, FB, GPalano, MPK, FO, GRicco, VR, RF, CP, GRaimondo, VL, GPelecca, TLC, LR, SG, MR, VA, AG, FTovoli, BernardoS, MB, LL, BenedettaS, MGuarino, VC, AI, FMarchetti, NR, MGiufrida, PC, ARocco, LM, NdM, FRP, AP, GPier, CCiulli, MScotti, IM, AP, VDP, EMC, AFacciorusso, RP, AFranceschi, LM, DC, CScorzoni, GS, AC, PPelizzo, FProcopio, ZLL, FN. Writing – original draft: SF, SG, ASangiovanni, AV, GC, AL, FC, ASaccomandi, MA, EP, MRB, MSF, CG, CC, FM, MDM, MM, VS, MCapasso, AMasotto, AFontana, MI, AR, MSerenari, AMega, AG, MCPT, MGarancini, SC, ED, PPerr, RS, MGiglio, CF, MDA, AT, DM, DN, GZimmitti, PG, LS, MConticchio, MZ, MRomano, FMilana, QLai, SP. Writing – review and editing: FG, AFrena, MRossi, GT, GZanus, EJ, RM, GS-B, PT, MAH, MV, MCrespi, LB, GGriseri, RIT, GLG, FAzzaroli, ARuzzenante, FR, EGG, MCescon, GN, RDV, AFerrero, FMorisio, FP, GGhittoni, CSaitta, FPelizzaro, GV, FGF, LA, LDC, UC, EB, DB, Fardito, FTrevisani. Supervision: SF, FTrevisani, FG.

Data availability statement

Data are available upon reasonable request to the corresponding author.

Acknowledgements

Italian Ministry of Health – RC 2024.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhepr.2025.101420>.

References

Author names in bold designate shared co-first authorship

- [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBO-CAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209–249.
- [2] Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology* 2018;67:123–133.
- [3] Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012;57:675–688.
- [4] Torzilli G, Belghiti J, Kokudo N, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. *Ann Surg* 2013;257:929–937.
- [5] Shiina S, Sato K, Tateishi R, et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. *Can J Gastroenterol Hepatol* 2018;2018:4756147.
- [6] Chen M-S, Li J-Q, Zheng Y, Guo R-P, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg* 2006;243:321–328.
- [7] Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. *J Hepatol* 2012;57:794–802.
- [8] Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg* 2010;252:903–912.
- [9] Fang Y, Chen W, Liang X, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014;29:193–200.

- [10] Takayama T, Hasegawa K, Izumi N, et al. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial). *Liver Cancer* 2022;11:209–218.
- [11] Cucchetti A, Piscaglia F, Cescon M, et al. Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma. *World J Gastroenterol* 2013;19:4106–4118.
- [12] Xu Q, Kobayashi S, Ye X, et al. Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients. *Sci Rep* 2014;4:1–9.
- [13] Li J-K, Liu X-H, Cui H, et al. Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: a systematic review and meta-analysis. *Mol Clin Oncol* 2020;12:15–22.
- [14] Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. *Liver Cancer* 2021;10:181–223.
- [15] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2018;69:182–236.
- [16] Cabibbo G, Daniele B, Borzio M, et al. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice treatment guidelines of the Italian association for the study of the liver (AISF), Italian association of medical Oncology (AIOM), Italian association of hepato-bilio-pancreatic surgery (AICEP), Italian association of hospital gastroenterologists (AIGO), Italian association of radiology and clinical Oncology (AIRO), Italian society of pathological anatomy and diagnostic cytology (SIAPeC-IAP), Italian society of surgery (SIC), Italian society of Gastroenterology (SIGE), Italian society of medical and interventional radiology (SIRM), Italian organ transplant society (SITO), and association of patients with hepatitis and liver disease (EpaC) – Part I – surgical treatments. *Dig Liver Dis* 2024;56:223–234.
- [17] Cucchetti A, Piscaglia F, Cescon M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. *J Hepatol* 2013;59:300–307.
- [18] Zhou Z, Lei J, Li B, et al. Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single nodule <2 cm): a single-center study. *Eur J Gastroenterol Hepatol* 2014;26:339–344.
- [19] Buell JF, Cherqui D, Geller DA, et al. The international position on laparoscopic liver surgery: the Louisville statement, 2008. *Ann Surg* 2009;250:825–830.
- [20] Liu R, Wakabayashi G, Kim H-J, et al. International consensus statement on robotic hepatectomy surgery in 2018. *World J Gastroenterol* 2019;25:1432–1444.
- [21] Famularo S, Donadon M, Cipriani F, et al. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience. *Updates Surg* 2020;72:399–411.
- [22] von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007;4:e296.
- [23] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–383.
- [24] Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative Oncology group. *Am J Clin Oncol* 1982;5:649–656.
- [25] Neeman E, Gresham G, Ovasapian N, et al. Comparing physician and nurse eastern cooperative Oncology group performance status (ECOG-PS) ratings as predictors of clinical outcomes in patients with cancer. *Oncologist* 2019;24:e1460–e1466.
- [26] Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology* 2000;31:864–871.
- [27] Child CG, Turcotte JG. Surgery and portal hypertension. *Major Probl Clin Surg* 1964;1:1–85.
- [28] Strasberg SM, Belghiti J, Clavien P-A, et al. The Brisbane 2000 terminology of liver anatomy and resections. *HPB* 2000;2:333–339.
- [29] Newgard CD, Lewis RJ. Missing data: how to best account for what is not known. *JAMA* 2015;314:940–941.
- [30] Kleinke K, Reinecke J, Salfrán D, et al. Applied multiple imputation: advances, Pitfalls, new developments and applications in R. Berlin: Springer Nature; 2020.
- [31] Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. *Stat Med* 2014;33:1242–1258.
- [32] Austin PC, Schuster T. The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: a simulation study. *Stat Methods Med Res* 2016;25:2214–2237.
- [33] Wang K, Wang R, Liu S, et al. Comparison of the safety and efficacy of hepatic resection and radiofrequency ablation in the treatment of single small hepatocellular carcinoma: systematic review and meta-analysis. *Transl Cancer Res* 2022;11:580–590.
- [34] Pompili M, Saviano A, de Matthaeis N, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤ 3 cm. Results of a multicenter Italian survey. *J Hepatol* 2013;59:89–97.
- [35] Yang J, Guo W, Lu M. Recent perspectives on the mechanism of recurrence after ablation of hepatocellular carcinoma: a mini-review. *Front Oncol* 2022;12:895678.
- [36] Famularo S, Ceresoli M, Giani A, et al. Is it just a matter of surgical extension to achieve the cure of hepatocarcinoma? A meta-analysis of propensity-matched and randomized studies for anatomic versus parenchyma-sparing liver resection. *J Gastrointest Surg* 2021;25:94–103.
- [37] Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. *Ann Surg* 2021;273:564–571.
- [38] Kawaguchi Y, Hasegawa K, Hagiwara Y, et al. Effect of diameter and number of hepatocellular carcinomas on survival after resection, transarterial chemoembolization, and ablation. *Am J Gastroenterol* 2021;116:1698–1708.
- [39] Giulianti F, Ratti F, Panettieri E, et al. Short and long-term outcomes after minimally invasive liver resection for single small hepatocellular carcinoma: an analysis of 714 patients from the IGoMILS (Italian Group of Minimally Invasive Liver Surgery) registry. *HPB* 2023;25:674–683.
- [40] Vitale A, Cabibbo G, Iavarone M, et al. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. *Lancet Oncol* 2023;24:e312–e322.

Keywords: Small HCC; Mini-invasive liver surgery; Thermoablation; Treatment hierarchy; HE.RC.O.LE.S; ITA.LI.CA.

Received 19 November 2024; received in revised form 24 March 2025; accepted 31 March 2025; Available online 25 April 2025

Appendix 1. HE.RC.O.LE.S and ITA.LI.CA Contributors

Francesco Razionale¹, Gabriele Missale², Andrea Olivani², Gloria Allegrini³, Pierluigi Romano⁴, Calogero Cammà⁵, Ciro Celsa⁵, Paolo Giuffrida⁵, Carmelo Marco Giacchetto⁵, Gabriele Rancatore⁵, Maria Vittoria Grassini⁶, Roberta Ciccio⁵, Alessandro Grova⁵, Mauro Salvato⁵, Riccardo De Carlis⁶, Francesca Ratti⁷, Lucia Napoli⁸, Alberto Borghi⁸, Fabio Conti⁸, Luca Ielasi⁸, Marco Ferronato⁸, Nicola Reggiori⁸, Fabio Farinati⁹, Federica Bertellini⁹, Giorgio Palano⁹, Maria Piera Kitenge⁹, Filippo Oliveri¹⁰, Gabriele Riccio¹⁰, Veronica Romagnoli¹⁰, Roberto Filomia¹¹, Concetta Pitrone¹¹, Giovanni Raimondo¹¹, Valentina Lauria¹², Giorgio Pelecca¹², Tancredi Li Cavoli¹³, Lucia Ragozzino¹³, Stefano Gitto¹³, Martina Rosi¹³, Valentina Adotti¹³, Alessandro Granito¹⁴, Francesco Tovoli¹⁴, Bernardo Stefanini¹⁴, Maurizio Biselli¹⁵, Lorenzo Lani¹⁵, Benedetta Stefanini¹⁵, Maria Guarino¹⁶, Valentina Cossiga¹⁶, Alessandro Inno¹⁷, Fabiana Marchetti¹⁷, Nadia Russolillo¹⁸, Mario Giuffrida¹⁹, Pietro Coccolini²⁰, Alba Rocco²⁰, Luca Marzi²¹, Nicoletta de Matthaeis²², Francesca Romana Ponziani²², Andrea Pasta^{23,24}, Giulia Pieri^{23,24}, Cristina Ciulli²⁵, Mauro Scotti²⁵, Ivan Marchitelli²⁶, Alberto Porro²⁷, Valerio De Peppo²⁸, Ester Marina Cela²⁹, Antonio Facciorusso²⁹, Renato Patrone³⁰, Angelo Franceschi³¹, Laura Marinelli³², Davide Cosola³³, Chiara Scorzoni³⁴, Giulia Scandali³⁴, Annachiara Casella³⁵, Patrizia Pelizzo³⁶, Fabio Propicio³⁷, Zoe Larghi Laurerio³⁸, Francesca Notte³⁹.

¹Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Catholic University of the Sacred Heart, Rome, Italy; ²Department of Medicine and Surgery, Infectious Diseases and Hepatology Unit, University of Parma and Azienda Ospedaliero-Universitaria of Parma, Parma, Italy; ³Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and C.R.C. "A.M. & A. Migliavacca Center for Liver Disease", Milan, Italy; ⁴Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padova, Second General Surgical Unit, Padova Teaching Hospital, Padua, Italy; ⁵Section of Gastroenterology and Hepatology. Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties (PROMISE), Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy; ⁶General Surgery and Abdominal Organ Transplantation, ASST Grande Ospedale Metropolitano Milano Niguarda; School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; ⁷Hepatobiliary Surgery Division, "Vita e Salute" University, Ospedale San Raffaele IRCCS, Milan, Italy; ⁸Department of Internal Medicine, Ospedale per gli Infermi di Faenza, Faenza, Italy; ⁹Department of Surgery, Oncology and Gastroenterology, Gastroenterology Unit, University of Padua, Padua, Italy; ¹⁰Department of Clinical and Experimental Medicine, Hepatology and Liver Physiopathology Laboratory, University Hospital of Pisa, Pisa, Italy; ¹¹Department of Clinical and Experimental Medicine, Clinical and Molecular Hepatology Unit, University of Messina,

Messina, Italy; ¹²Gastroenterology Unit, Belcolle Hospital, Viterbo, Italy; ¹³Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Florence, Florence, Italy; ¹⁴Medicine Unit, Bolognini Hospital, Seriate, Italy; ¹⁵Unit of Semeiotics, Liver and Alcohol Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ¹⁶Department of Clinical Medicine and Surgery, Diseases of the Liver and Biliary System Unit, University of Naples "Federico II", Naples, Italy; ¹⁷Gastroenterology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy; ¹⁸Department of General and Oncological Surgery, Mauriziano Hospital "Umberto I", Turin, Italy; ¹⁹Department of General and Specialized Surgery, Division of General Surgery, Parma University Hospital, Parma, Italy; ²⁰Department of Clinical Medicine and Surgery, Hepato-Gastroenterology Unit, University of Naples "Federico II", Naples, Italy; ²¹Gastroenterology Unit, Bolzano Regional Hospital, Bolzano, Italy; ²²Liver Unit, CEMAD – Centro Malattie dell'Apparato Digerente, Medicina Interna e Gastroenterologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy; ²³Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy; ²⁴IRCCS Ospedale Policlinico San Martino, Genoa, Italy; ²⁵School of Medicine and Surgery, University of Milano-Bicocca; IRCCS San Gerardo dei Tintori Hospital, Monza, Italy; ²⁶Division of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy; ²⁷Division of Gastroenterology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ²⁸Division of Hepatobiliarypancreatic Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Italy; ²⁹Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, Foggia, Italy; ³⁰Division of Hepato-biliary-pancreatic, Minimally Invasive and Robotic surgery, and Transplantation Service Federico II University Hospital, Naples, Italy; ³¹HPB Surgical Unit, San Paolo Hospital, Savona, Italy; ³²HPB Surgery and Transplantation Unit, Department of Clinical and Experimental Medicine, Polytechnic University of Marche, Ancona, Italy; ³³Division of General Surgery, Department of Medical and Surgical Sciences, ASUGI, Trieste, Italy; ³⁴Liver Injury and Transplant Unit, Polytechnic University of Marche, Ancona, Italy; ³⁵Department of Hepato-Pancreatic-Biliary Surgery, "F. Miulli" General Regional Hospital, Acquaviva delle Fonti, Bari; Department of Medicine and Surgery, LUM University, Casamassima, Bari, Italy; ³⁶Department of Surgical, Oncological and Gastroenterological Science (DiSCOG), University of Padua, Hepatobiliary and Pancreatic Surgery Unit - Treviso Hospital, Italy; ³⁷Department of Hepatobiliary and General Surgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; ³⁸General Surgery and Organ Transplantation Unit, Sapienza University of Rome, Umberto I Polyclinic of Rome, Rome, Italy; ³⁹Department of General and Pediatric Surgery, Bolzano Central Hospital, Bolzano, Italy.